宝济药业-B今日盘中股价大幅上涨5.62%，引起了投资者的广泛关注。
消息面上，公司董事会主席兼控股股东集团成员刘彦君博士此前宣布，拟于三个月内通过公开市场增持公司股份，最高不超过3889.39万股H股，此举持续向市场释放了对公司长期价值的认可信号。同时，公司的注射用人玻璃酸酶已获国家药监局批准上市，为产品管线再添商业化品种，增强了未来的盈利预期。此外，公司的股份购回授权也已获得股东大会通过，公司表示回购资金合法合规且不影响正常运营。在多重利好因素的叠加作用下，市场对公司信心持续回暖，推动了股价的强势表现。
值得注意的是，在当前生物科技板块整体表现偏弱的背景下，宝济药业-B能够逆势走强，更多反映了公司层面具体催化剂的驱动作用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.